24/7 Market News Snapshot 28 February, 2025 – ImmunityBio, Inc. Common Stock (NASDAQ:IBRX)

February 28, 2025

DENVER, Colo., 28 February, 2025 (247marketnews.com) – (NASDAQ:IBRX) are discussed in this article.
ImmunityBio, Inc. (NASDAQ:IBRX) is experiencing a remarkable surge in stock performance, with today’s trading reflecting an increase of approximately 18.15%, rising from a previous close of $2.860 to a current price of $3.379. This upswing is accompanied by robust trading volume, with 2.53 million shares changing hands, indicating heightened investor enthusiasm. Market analysts suggest that the stock may continue its upward trajectory as it breaks through key resistance levels, although they advise caution as potential market corrections could occur.

Alongside its stock market performance, ImmunityBio has achieved a significant milestone by receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for its novel therapies, ANKTIVA® and CAR-NK (PD-L1 t-haNK). This designation is aimed at addressing lymphopenia in patients undergoing standard-of-care chemotherapy and radiotherapy, particularly in those with multiple relapses of locally advanced or metastatic pancreatic cancer.

ImmunityBio’s innovative therapies tackle a long-standing challenge in cancer treatment, as lymphopenia has hindered effective patient outcomes for over fifty years. Dr. Patrick Soon-Shiong, Founder of ImmunityBio, underscored the breakthrough potential of these therapies, which activate and proliferate essential immune cells to mount a robust anti-cancer response.

The company is poised to expedite its Biologics License Application (BLA) process, leveraging the advantages associated with the RMAT designation to further the progression of its transformative therapies. ANKTIVA and CAR-NK signify a shift in therapeutic strategies, aiming not only to combat established conditions but also to enhance the overall treatment landscape for patients in need of innovative care solutions. Through these advancements, ImmunityBio reinforces its commitment to revolutionizing cancer therapy and improving patient outcomes globally.

Related news for (IBRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.